Table 1.
Selection of published and ongoing clinical trials testing immune checkpoint blockade (ICB) in pancreatic cancer.
| Trial identifier | Cancer types | Treatment groups | Response | Reference |
|---|---|---|---|---|
| Completed | PDAC, NSCLC, Melanoma, CRC, renal cancer, ovarian cancer, gastric cancer, breast cancer | BMS-936559 (anti-PD-L1) | 0% (PDAC) | 21 |
| Completed | Previously treated PDAC | Ipilimumab | 0%, 1 delayed PR | 22 |
| Completed | Previously treated PDAC | Durvalumab (D; anti-PD-L1) vs. Durvalumab + Tremelimumab (T; anti-CTLA-4) | 0% 3% (D/T) PR | 20 |
| NCT03871959 | Advanced/meta-static PDAC/CRC | Pembrolizumab (Pe; anti-PD-1) vs. Pembrolizumab + Debio1143 (Db; SMAC mimetic) | pending | N/A |
| NCT03634332 | Previously treated PDAC | Pembrolizumab (Pe; anti-PD-1) vs. Pembrolizumab + PEGPH20 (hyaluronidase) | pending | N/A |
| NCT03767582 | Previously treated PDAC | Nivolumab (anti-PD-1) combination with BMS-813160 (CCR2/CCR5 Dual Antagonist) and GVAX | pending | N/A |
| NCT02777710 | Advanced/meta-static PDAC/CRC | Durvalumab (D; anti-PD-L1) vs. Durvalumab + Pexidartinib (P; kinase inhibitor against colony-stimulating factor-1 receptor; CSF1R) | pending | N/A |
| NCT03727880 | Resectable PDAC | Pembrolizumab (Pe; anti-PD-1) vs. Pembrolizumab + Defactinib (De; inhibitor against focal adhesion kinase, FAK) | pending | N/A |
PR partial response, NSCLC non-small cell lung cancer, CRC colorectal cancer.